PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study

Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3.

Source: Journal of Nuclear Medicine - December 17, 2020 Category: Nuclear Medicine Authors: Weber, M., Kurek, C., Barbato, F., Eiber, M., Maurer, T., Nader, M., Hadaschik, B., Grunwald, V., Herrmann, K., Wetter, A., Fendler, W. P. Tags: Clinical Source Type: research